1541 related articles for article (PubMed ID: 11845978)
41. Current treatment options in hairy cell leukemia and hairy cell leukemia variant.
Robak T
Cancer Treat Rev; 2006 Aug; 32(5):365-76. PubMed ID: 16781083
[TBL] [Abstract][Full Text] [Related]
42. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes.
Del Giudice I; Matutes E; Morilla R; Morilla A; Owusu-Ankomah K; Rafiq F; A'Hern R; Delgado J; Bazerbashi MB; Catovsky D
Haematologica; 2004 Mar; 89(3):303-8. PubMed ID: 15020268
[TBL] [Abstract][Full Text] [Related]
43. Successful treatment of patients with hairy cell leukemia (HCL) using a single cycle of 2-chloro-2'-deoxyadenosine (CdA).
Jehn U; Gawaz M; Grunewald R; Hill W; Lorenz B; Stôtzer O
Anticancer Res; 1993; 13(5C):1809-14. PubMed ID: 7903521
[TBL] [Abstract][Full Text] [Related]
44. CD5+ chronic B-cell leukemia with features intermediate to chronic lymphocytic leukemia and hairy cell leukemia.
Aljurf M; Cornbleet PJ; Michel F
Hematol Pathol; 1994; 8(3):99-109. PubMed ID: 7527021
[TBL] [Abstract][Full Text] [Related]
45. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
[TBL] [Abstract][Full Text] [Related]
46. Reduced numbers of CD8+ T cells and B cell-expression of Leu-8 antigen in peripheral blood of patients with primary biliary cirrhosis.
Moreno-Otero R; Civeira MP; Suou T; Kanof ME; James SP; Jones EA
Hepatogastroenterology; 1994 Jun; 41(3):239-43. PubMed ID: 7525431
[TBL] [Abstract][Full Text] [Related]
47. The disease with hope: hairy cell leukemia.
Becker SE
Clin J Oncol Nurs; 2007 Oct; 11(5):731-5. PubMed ID: 17962181
[TBL] [Abstract][Full Text] [Related]
48. [Hairy cell leukemia in young patients].
Al'-Radi LS; Samoĭlova RS; Tikhonova LIu; Diagileva OA; Naumova IN; Kaplanskaia IB; Varlamova EIu
Ter Arkh; 2008; 80(12):53-8. PubMed ID: 19227908
[TBL] [Abstract][Full Text] [Related]
49. Absolute values of dendritic cell subsets in bone marrow, cord blood, and peripheral blood enumerated by a novel method.
Szabolcs P; Park KD; Reese M; Marti L; Broadwater G; Kurtzberg J
Stem Cells; 2003; 21(3):296-303. PubMed ID: 12743324
[TBL] [Abstract][Full Text] [Related]
50. Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro.
al-Katib A; Mohammad RM; Dan M; Hussein ME; Akhtar A; Pettit GR; Sensenbrenner LL
Exp Hematol; 1993 Jan; 21(1):61-5. PubMed ID: 8093352
[TBL] [Abstract][Full Text] [Related]
51. Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia.
Arun B; Curti BD; Longo DL; Stevens D; Alvord WG; Gause BL; Watson T; Kopp WC; Janik JE
Cancer J Sci Am; 2000; 6(1):21-4. PubMed ID: 10696734
[TBL] [Abstract][Full Text] [Related]
52. Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis.
Knapp W; Strobl H; Majdic O
Cytometry; 1994 Dec; 18(4):187-98. PubMed ID: 7534675
[TBL] [Abstract][Full Text] [Related]
53. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
[TBL] [Abstract][Full Text] [Related]
54. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
Zelezníková T; Babusíková O
Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
[TBL] [Abstract][Full Text] [Related]
55. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
[TBL] [Abstract][Full Text] [Related]
56. Immunophenotypic characteristics of T-acute lymphoblastic leukemia cells in relation to DPP IV enzyme expression.
Klobusická M; Babusíková O
Neoplasma; 1998; 45(4):237-42. PubMed ID: 9890667
[TBL] [Abstract][Full Text] [Related]
57. Hairy cell leukemia: current concepts.
Cannon T; Mobarek D; Wegge J; Tabbara IA
Cancer Invest; 2008 Oct; 26(8):860-5. PubMed ID: 18798068
[TBL] [Abstract][Full Text] [Related]
58. Cladribine in hairy cell leukemia.
Belani R; Saven A
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
[TBL] [Abstract][Full Text] [Related]
59. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
[TBL] [Abstract][Full Text] [Related]
60. Recipient-derived cells after cord blood transplantation: dynamics elucidated by multicolor FACS, reflecting graft failure and relapse.
Watanabe N; Takahashi S; Ishige M; Ishii Y; Ooi J; Tomonari A; Tsukada N; Konuma T; Kato S; Sato A; Tojo A; Nakauchi H
Biol Blood Marrow Transplant; 2008 Jun; 14(6):693-701. PubMed ID: 18489995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
